{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:21:25Z","timestamp":1776280885387,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1016\/j.ejon.2004.06.005","type":"journal-article","created":{"date-parts":[[2004,9,2]],"date-time":"2004-09-02T23:54:10Z","timestamp":1094169250000},"page":"S4-S15","source":"Crossref","is-referenced-by-count":15,"special_numbering":"S1","title":["Development of and clinical experience with capecitabine (Xeloda\u00ae) in the treatment of solid tumours"],"prefix":"10.1016","volume":"8","author":[{"given":"Cora N.","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Holland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejon.2004.06.005_bib1","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/1097-0142(19950415)75:8<2165::AID-CNCR2820750821>3.0.CO;2-W","article-title":"A new complication of chemotherapy administered via permanent indwelling central venous catheter","volume":"75","author":"Ardalan","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib2","doi-asserted-by":"crossref","unstructured":"Arkenau, H.-T., Schmoll, H., Kubicka, S., Seufferlein, T., Reichardt, P., Freier, W., Graeven, U., Grothey, A., Porschen, R., 2004. Phase III trial of infusional 5-fluorouracil\/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): results of an interim safety analysis. Proceedings of the American Society of Clinical Oncology, vol. 23; p. 257 (abstract 3546).","DOI":"10.1200\/jco.2004.22.14_suppl.3546"},{"key":"10.1016\/j.ejon.2004.06.005_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cncr.11910","article-title":"Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma","volume":"100","author":"Bajetta","year":"2004","journal-title":"Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejon.2004.06.005_bib4","first-page":"143","article-title":"Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer","volume":"11","author":"Bangemann","year":"2000","journal-title":"Annals of Oncology"},{"issue":"Suppl. 6","key":"10.1016\/j.ejon.2004.06.005_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1634\/theoncologist.2002-0029","article-title":"Moving forward with capecitabine","volume":"7","author":"Biganzoli","year":"2002","journal-title":"The Oncologist"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.005_bib6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1634\/theoncologist.6-1-56","article-title":"The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer","volume":"6","author":"Blum","year":"2001","journal-title":"The Oncologist"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.005_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.005_bib8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of oral capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0959-8049(03)00266-1","article-title":"An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced\/inflammatory breast cancer","volume":"39","author":"Bonnefoi","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejon.2004.06.005_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.6-suppl_4-12","article-title":"Answering patients\u2019 needs","volume":"6","author":"Borner","year":"2001","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejon.2004.06.005_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin","volume":"38","author":"Borner","year":"2002","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib12","doi-asserted-by":"crossref","unstructured":"Borner, M.M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrman, R., Pestalozzi, B.C., Saletti, P., Hanselmann, S., M\u00fcller, S., Brauchli, P., Castiglione-Gertsch, M., Goldhirsch, A., Roth, A.D., for the Swiss Group for Clinical Cancer Research, 2002b. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. Journal of Clinical Oncology 20(7), 1759\u20131766.","DOI":"10.1200\/JCO.2002.07.087"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.005_bib13","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/cncr.20154","article-title":"New systemic frontline treatment for metastatic colorectal carcinoma","volume":"100","author":"Braun","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejon.2004.06.005_bib14","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1998.16.5.1795","article-title":"Preliminary studies of a novel oral fluoropyrimidine carbamate","volume":"16","author":"Budman","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.005_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.1994.12.1.14","article-title":"Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer","volume":"12","author":"Buroker","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 5","key":"10.1016\/j.ejon.2004.06.005_bib16","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1359-6349(03)90279-5","article-title":"Preliminary data on weekly irinotecan with continuous oral administration of capecitabine in metastatic colorectal cancer","volume":"1","author":"Burris","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib17","doi-asserted-by":"crossref","unstructured":"Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendrick, J., Maroun, J., Marshall, J., Osterwalder, B., P\u00e9rez-Manga, G., Rosso, R., Rougier, P., Schilsky, R.L., on behalf of the Capecitabine Colorectal Cancer Study Group, 2002. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Annals of Oncology 13(4), 566\u2013575.","DOI":"10.1093\/annonc\/mdf089"},{"key":"10.1016\/j.ejon.2004.06.005_bib18","doi-asserted-by":"crossref","unstructured":"Cassidy, J., Scheithauer, W., McKendrick, J., Kr\u00f6ning, H., Nowacki, M.P., Seitz, J.F., Twelves, C., Van Hazel, G., Wong, A., D\u00edaz-Rubio, E., On Behalf Of X-act Study Investigators, 2004a. Capecitabine (X) vs bolus 5-FU\/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings of the American Society of Clinical Oncology, vol. 23 (abstract 3509).","DOI":"10.1200\/jco.2004.22.14_suppl.3509"},{"key":"10.1016\/j.ejon.2004.06.005_bib19","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin)","volume":"22","author":"Cassidy","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib20","first-page":"121","article-title":"Capecitabine (Xeloda) as treatment after failure to taxanes for metastatic breast cancer","volume":"19","author":"Cervantes","year":"2000","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib21","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib22","doi-asserted-by":"crossref","unstructured":"Delord, J.P., Pierga, J.Y., Dieras, V., Bertheault-Cvitkovic, F., Turpin, F.L., Lokiec, F., Canal, P., Chatelut, E., Guimbaud, R., Cornen, X., Mouri, Z., Bugat, R., 2002. Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastro-intestinal tumors: preliminary results. Proceedings of the American Society of Clinical Oncology 21 (abstract 397).","DOI":"10.1016\/S0959-8049(01)80764-4"},{"issue":"9209","key":"10.1016\/j.ejon.2004.06.005_bib23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejon.2004.06.005_bib24","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2002.02.049","article-title":"Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer","volume":"20","author":"Dunst","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib25","first-page":"260","article-title":"Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer","volume":"23","author":"Dunst","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<127::AID-IJC22>3.0.CO;2-6","article-title":"Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5\u2032-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models","volume":"83","author":"Endo","year":"1999","journal-title":"International Journal of Cancer"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.005_bib27","first-page":"2223","article-title":"Pharmacokinetics of 5-fluorouracil administered orally, by rapid i.v. and by slow infusion","volume":"40","author":"Fraile","year":"1980","journal-title":"Cancer Research"},{"key":"10.1016\/j.ejon.2004.06.005_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib30","first-page":"254","article-title":"Capecitabine\/irinotecan (CapIri) and capecitabine, oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy","volume":"23","author":"Grothey","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.005_bib31","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer","volume":"19","author":"Hoff","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.005_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","article-title":"Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts","volume":"55","author":"Ishikawa","year":"1998","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.005_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1006497231579","article-title":"Capecitabine","volume":"18","author":"Ishitsuka","year":"2000","journal-title":"Investigational New Drugs"},{"issue":"4","key":"10.1016\/j.ejon.2004.06.005_bib34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00001813-200204000-00009","article-title":"Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation\u2014a phase II study","volume":"13","author":"Jakob","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.005_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/14737140.3.2.137","article-title":"Role of capecitabine (Xeloda\u00ae) in breast cancer","volume":"3","author":"Kaklamani","year":"2003","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"1","key":"10.1016\/j.ejon.2004.06.005_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib37","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","article-title":"Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer","volume":"16","author":"Mackean","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.ejon.2004.06.005_bib38","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/sj.bjc.6600809","article-title":"Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer","volume":"88","author":"Mader","year":"2003","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1526-8209(11)70270-1","article-title":"Capecitabine\/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer","volume":"3","author":"Maung","year":"2003","journal-title":"Clinical Breast Cancer"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.005_bib40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib41","first-page":"111a","article-title":"Phase I study of vinorelbine (and capecitabine in advanced breast cancer","volume":"19","author":"Nole","year":"2000","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"10 Suppl. 12","key":"10.1016\/j.ejon.2004.06.005_bib42","first-page":"17","article-title":"Capecitabine and docetaxel in advanced breast cancer","volume":"16","author":"O\u2019Shaughnessy","year":"2002","journal-title":"Oncology (Huntingt)"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib43","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, open-label, phase II trial of oral capecitabine (Xeloda\u00ae) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O\u2019Shaughnessy","year":"2001","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1016\/j.ejon.2004.06.005_bib44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib45","doi-asserted-by":"crossref","unstructured":"Pagani, O., Sessa, C., Longhi, S., Nol\u00e8, F., Crivellari, D., Thurlimann, B., Hess, D., Graffeo, R., Goldhirsch, A., on behalf of the International Breast Cancer Study Group Scientific Committee, 2001. Dose-finding study of docetaxel and doxorubicin day 1 and 8 plus capecitabine day 1 to 14 as first line treatment in advanced breast cancer. European Journal of Cancer 37(Suppl. 6), 194 (abstract 711).","DOI":"10.1016\/S0959-8049(01)81203-X"},{"key":"10.1016\/j.ejon.2004.06.005_bib46","first-page":"271","article-title":"Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)","volume":"23","author":"Patt","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib47","first-page":"759","article-title":"Safety and activity of capecitabine in elderly patients with advanced breast cancer","volume":"22","author":"Procopio","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"Suppl. 5","key":"10.1016\/j.ejon.2004.06.005_bib48","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1359-6349(03)90310-7","article-title":"Combination of irinotecan and capecitabine as first line treatment in advanced colorectal cancer","volume":"1","author":"Punt","year":"2003","journal-title":"European Journal of Cancer"},{"issue":"8","key":"10.1016\/j.ejon.2004.06.005_bib49","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib51","first-page":"941","article-title":"Effects of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients","volume":"4","author":"Reigner","year":"1998","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.005_bib52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002800050900","article-title":"Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients","volume":"43","author":"Reigner","year":"1999","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"2","key":"10.1016\/j.ejon.2004.06.005_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.ejon.2004.06.005_bib53","unstructured":"Sawada, N., Fujimoto-Ouchi, K., Ishikawa, T., Tanaka, Y., Ishituka, H., 2002. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proceedings of the American Association of Cancer Research (abstract 5388)."},{"issue":"Suppl. 4","key":"10.1016\/j.ejon.2004.06.005_bib54","first-page":"12","article-title":"Drug interaction of capecitabine and phenytoin in the therapy of cerebral and visceral metastatic breast cancer","volume":"11","author":"Schaller","year":"2000","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1016\/j.ejon.2004.06.005_bib55","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.2003.09.016","article-title":"Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"21","author":"Scheithauer","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib56","doi-asserted-by":"crossref","unstructured":"Scheithauer, W., McKendrick, J., Begbie, S., Broner, M., Burns, W.I., Burris, H.A., Cassidy, J., Jodrell, D., Koralewski, P., Levine, E.L., Marschner, N., Maroun, J., Garcia-Alfonso, P., Tujakowski, J., van Hazel, G., Wong, A., Zaluski, J., Twelves, C., for the X-ACT Study Group, 2003b. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of Oncology 14 (12), 1735\u20131743.","DOI":"10.1093\/annonc\/mdg500"},{"issue":"Suppl. 5","key":"10.1016\/j.ejon.2004.06.005_bib57","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0959-8049(96)00335-8","article-title":"Development of treatment for advanced colorectal cancer","volume":"32A","author":"Schmoll","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"Suppl. 6","key":"10.1016\/j.ejon.2004.06.005_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_6-20","article-title":"Single-agent capecitabine","volume":"7","author":"Seidman","year":"2002","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejon.2004.06.005_bib60","first-page":"313","article-title":"Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC)","volume":"23","author":"Shi","year":"2004","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.ejon.2004.06.005_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.11925","article-title":"Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine","volume":"100","author":"Shields","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib62","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda\u00ae) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"British Journal of Cancer"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib63","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/annonc\/mdg376","article-title":"Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer","volume":"14","author":"Tewes","year":"2003","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.005_bib64","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","article-title":"Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer","volume":"18","author":"Van Cutsem","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib65","doi-asserted-by":"crossref","unstructured":"Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., McKendrick, J., Osterwalder, B., Perez-Manga, G., Russon, R., Rougier, P., Schiegel, W.H., Seitiz, J.-F., Thompson, P., Vieitez, J.M., Weitzel, C., Harper, P., for the Xeloda Colorectal Cancer Study Group, 2001. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 19 (21), 4097\u20134106.","DOI":"10.1200\/JCO.2001.19.21.4097"},{"key":"10.1016\/j.ejon.2004.06.005_bib66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","article-title":"Oral capecitabine vs intravenous 5-fluorouracil and leucovorin","volume":"90","author":"Van Cutsem","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejon.2004.06.005_bib67","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.11203","article-title":"Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma","volume":"97","author":"Venturini","year":"2003","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.ejon.2004.06.005_bib68","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1200\/JCO.2003.08.008","article-title":"Venous thromboembolism associated with long-term use of central venous catheters in cancer patients","volume":"21","author":"Verso","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.ejon.2004.06.005_bib69","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1200\/JCO.1999.17.6.1915","article-title":"Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies","volume":"17","author":"Villalona-Calero","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib70","first-page":"58b","article-title":"Phase I study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer","volume":"20","author":"Welt","year":"2001","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"key":"10.1016\/j.ejon.2004.06.005_bib71","first-page":"120","article-title":"Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast cancer","volume":"19","author":"Wong","year":"2000","journal-title":"Proceedings of American Society of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.ejon.2004.06.005_bib72","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdg360","article-title":"Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"14","author":"Zeuli","year":"2003","journal-title":"Annals of Oncology"}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388904000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:20:04Z","timestamp":1585869604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388904000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":72,"alternative-id":["S1462388904000523"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2004.06.005","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}